In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SyStemix Inc.

Division of Novartis AG

Latest From SyStemix Inc.

StemCells Inc. Prepares For An Expanding R&D Program

The California-based biotech has added additional positions to its executive management team as it broadens its clinical development programs to include multi-center, control-arm trials.

BioPharmaceutical Business Strategies

Genzyme Breaks a Biotech Taboo: The Hostile Bid For AnorMED

In late August, Genzyme launched a hostile bid for AnorMED, a Canadian biotech with an unpartnered stem cell mobilizer called MOZOBIL currently in Phase III clinical trials. When Millennium Pharmaceuticals Inc. jumped in with a higher offer, it set off a bidding war that has been dubbed "The battle of Boston". Ultimately, Genzyme prevailed, but in deciding to go directly to AnorMED's shareholders with its bid, that company's management broke one of the last taboos of biotech M&A. The move illustrates business development execs' desperate need to nab suitable assets that might help cure pipeline woes. Indeed, it appears unencumbered late stage assets are now so rare that their value may exceed estimates ascribed by the market; and this is true even if the people working on that asset are lost, as typically occurs following unsolicited offers.
BioPharmaceutical Business Strategies

Redefining the Stem Cell Opportunity

Small companies are now trying to leverage the value of both embryonic stem cells and adult stem cells, as genomics tools and for toxicology screening. At the same time, stem cells are gradually making their way into human testing, leading to an even more urgent need to understand the role that cytokines and growth factors play in signaling cells to differentiate. In fact, there's a growing recognition that the ultimate pharma opportunity may lie in selling drug cocktails that control cell differentiation, not in making and selling cells. Because dormant adult stem cells reside in tissues and in circulation, researchers are even beginning to envision applications where transplanted replacement cells are not needed at all.
BioPharmaceutical Manufacturing

Coulter Cellular Therapies Inc.

Coulter Cellular Therapies is developing optimized methods of extracting stem cells for stem cell transplantation.
BioPharmaceutical Regenerative Medicine
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Michael Perry, PhD, Pres. & CEO
  • Contact Info
  • SyStemix Inc.
    Phone: (415) 856-3400
    3400 W. Bayshore Road
    Palo Alto, CA 94303-